Literature DB >> 27418646

European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.

Pier Luigi Zinzani1, Lionel Karlin2, John Radford3, Dolores Caballero4, Paul Fields5, Martine E D Chamuleau6, Francesco d'Amore7, Corinne Haioun8, Catherine Thieblemont9, Eva González-Barca10, Carlos Grande García11, Peter W Johnson12, Gustaaf W van Imhoff13, Thomas Ng14, Karen Dwyer15, Franck Morschhauser16.   

Abstract

Entities:  

Keywords:  aggressive non-Hodgkin lymphoma; anti-CCR4 monoclonal antibody; mogamulizumab; peripheral T-cell lymphoma

Mesh：

Substances：

Year:  2016        PMID： 27418646      PMCID： PMC5046662          DOI： 10.3324/haematol.2016.146977

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells.

Authors:  J J Campbell; G Haraldsen; J Pan; J Rottman; S Qin; P Ponath; D P Andrew; R Warnke; N Ruffing; N Kassam; L Wu; E C Butcher
Journal:  Nature       Date:  1999-08-19       Impact factor: 49.962

2.  Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Authors:  Bertrand Coiffier; Barbara Pro; H Miles Prince; Francine Foss; Lubomir Sokol; Matthew Greenwood; Dolores Caballero; Peter Borchmann; Franck Morschhauser; Martin Wilhelm; Lauren Pinter-Brown; Swaminathan Padmanabhan; Andrei Shustov; Jean Nichols; Susan Carroll; John Balser; Barbara Balser; Steven Horwitz
Journal:  J Clin Oncol       Date:  2012-01-23       Impact factor: 44.544

3.  Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials.

Authors:  P A Tang; G R Pond; E X Chen
Journal:  Ann Oncol       Date:  2009-10-29       Impact factor: 32.976

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

Authors:  Owen A O'Connor; Steven Horwitz; Tamás Masszi; Achiel Van Hoof; Peter Brown; Jeannette Doorduijn; Georg Hess; Wojciech Jurczak; Poul Knoblauch; Shanta Chawla; Gajanan Bhat; Mi Rim Choi; Jan Walewski; Kerry Savage; Francine Foss; Lee F Allen; Andrei Shustov
Journal:  J Clin Oncol       Date:  2015-06-22       Impact factor: 44.544

6.  Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT).

Authors:  Seth R Stevens; Malcolm S Ke; Eileen J Parry; Julie Mark; Kevin D Cooper
Journal:  Arch Dermatol       Date:  2002-01

Review 7.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

Authors:  Elias Campo; Steven H Swerdlow; Nancy L Harris; Stefano Pileri; Harald Stein; Elaine S Jaffe
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

8.  Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

Authors:  Owen A O'Connor; Barbara Pro; Lauren Pinter-Brown; Nancy Bartlett; Leslie Popplewell; Bertrand Coiffier; Mary Jo Lechowicz; Kerry J Savage; Andrei R Shustov; Christian Gisselbrecht; Eric Jacobsen; Pier Luigi Zinzani; Richard Furman; Andre Goy; Corinne Haioun; Michael Crump; Jasmine M Zain; Eric Hsi; Adam Boyd; Steven Horwitz
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

9.  CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified.

Authors:  Takashi Ishida; Hiroshi Inagaki; Atae Utsunomiya; Yoshifusa Takatsuka; Hirokazu Komatsu; Shinsuke Iida; Genji Takeuchi; Tadaaki Eimoto; Shigeo Nakamura; Ryuzo Ueda
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

10.  Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.

Authors:  Fredrik Ellin; Jenny Landström; Mats Jerkeman; Thomas Relander
Journal:  Blood       Date:  2014-07-08       Impact factor: 22.113
View more
  12 in total

1.  Identifying potential factors of variable response to mogamulizumab in adult T-cell leukemia/lymphoma between Japanese and other populations.

Authors:  Murali Janakiram; Milos D Miljkovic
Journal:  Haematologica       Date:  2019-05       Impact factor: 9.941

2.  Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.

Authors:  Dai Maruyama; Kensei Tobinai; Michinori Ogura; Toshiki Uchida; Kiyohiko Hatake; Masafumi Taniwaki; Kiyoshi Ando; Kunihiro Tsukasaki; Takashi Ishida; Naoki Kobayashi; Kenichi Ishizawa; Yoichi Tatsumi; Koji Kato; Toru Kiguchi; Takayuki Ikezoe; Eric Laille; Tokihiro Ro; Hiromi Tamakoshi; Sanae Sakurai; Tomoko Ohtsu
Journal:  Int J Hematol       Date:  2017-06-29       Impact factor: 2.490

3.  Invariant NKT Cells Promote the Development of Highly Cytotoxic Multipotent CXCR3+CCR4+CD8+ T Cells That Mediate Rapid Hepatocyte Allograft Rejection.

Authors:  Jason M Zimmerer; Bryce A Ringwald; Sachi R Chaudhari; Jing Han; Chelsea M Peterson; Robert T Warren; Madison M Hart; Mahmoud Abdel-Rasoul; Ginny L Bumgardner
Journal:  J Immunol       Date:  2021-11-22       Impact factor: 5.426

Review 4.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

Review 5.  What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?

Authors:  Julien Catherine; Florence Roufosse
Journal:  Semin Immunopathol       Date:  2021-05-19       Impact factor: 9.623

6.  Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies.

Authors:  Ting Zhang; Jing Sun; Jinying Li; Yunuo Zhao; Tao Zhang; Ruoning Yang; Xuelei Ma
Journal:  BMC Cancer       Date:  2021-05-26       Impact factor: 4.430

7.  Harnessing immunotherapy for pediatric T-cell malignancies.

Authors:  Caroline Diorio; David T Teachey
Journal:  Expert Rev Clin Immunol       Date:  2020-02-27       Impact factor: 5.124

8.  E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study.

Authors:  Ken Ohmachi; Kiyoshi Ando; Michinori Ogura; Toshiki Uchida; Kensei Tobinai; Dai Maruyama; Masayuki Namiki; Tadashi Nakanishi
Journal:  Cancer Sci       Date:  2018-02-26       Impact factor: 6.716

Review 9.  Targeted Approaches to T-Cell Lymphoma.

Authors:  Sean Harrop; Chathuri Abeyakoon; Carrie Van Der Weyden; H Miles Prince
Journal:  J Pers Med       Date:  2021-05-27

Review 10.  Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review.

Authors:  Shinichi Makita; Akiko Miyagi Maeshima; Dai Maruyama; Koji Izutsu; Kensei Tobinai
Journal:  Onco Targets Ther       Date:  2018-04-20       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.